Edition:
United States

EnteroMedics Inc (ETRM.OQ)

ETRM.OQ on NASDAQ Stock Exchange Capital Market

8.90USD
17 Jan 2017
Change (% chg)

-- (--)
Prev Close
$8.90
Open
--
Day's High
--
Day's Low
--
Volume
34,199
Avg. Vol
348,605
52-wk High
$132.30
52-wk Low
$1.76

ETRM.OQ

Chart for ETRM.OQ

About

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to... (more)

Overall

Beta: 2.11
Market Cap(Mil.): $21.26
Shares Outstanding(Mil.): 2.39
Dividend: --
Yield (%): --

Financials

  ETRM.OQ Industry Sector
P/E (TTM): -- 61.22 30.46
EPS (TTM): -178.40 -- --
ROI: -368.81 7.14 14.82
ROE: -577.62 10.67 16.24

BRIEF-Enteromedics is canceling special meeting scheduled on Oct 19 - SEC filing

* Enteromedics Is canceling special meeting scheduled on Oct 19 due to lack of sufficent number of votes in favor of some proposals - SEC filing Source text - (http://bit.ly/2e7tA5f) Further company coverage:

Oct 19 2016

BRIEF-EnteroMedics appoints Dan Gladney as chairman of the board of directors

* Announces appointment of Dan Gladney as chairman of the board of directors

Sep 27 2016

BRIEF-EnteroMedics names Scott Youngstrom as CFO

* EnteroMedics announces appointment of Scott Youngstrom as chief financial officer and chief compliance officer

Sep 07 2016

BRIEF-CVI Investments Inc reports 9.9 pct passive stake in Enteromedics Inc

* CVI Investments Inc reports 9.9 pct passive stake in enteromedics inc, as of August 18, 2016 - Sec Filing Source - http://bit.ly/2cetnP4 Further company coverage:

Aug 26 2016

BRIEF-Enteromedics names Gary Blackford to board of directors

* Enteromedics announces appointment of Gary Blackford to its board of directors Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Aug 17 2016

BRIEF-EnteroMedics publishes 24 month recharge clinical study data in obesity surgery

* VBloc therapy demonstrates durable weight loss, reduction of comorbidities, and favorable safety profile at 24 months

Aug 15 2016

BRIEF-Enteromedics Q2 loss per share $0.49

* Q2 sales $276,000 Source text for Eikon: Further company coverage:

Aug 04 2016

Earnings vs. Estimates